Emergent Biosolutions, Inc. (EBS) Upgraded to “Buy” by BidaskClub

BidaskClub upgraded shares of Emergent Biosolutions, Inc. (NYSE:EBS) from a hold rating to a buy rating in a report issued on Saturday.

Separately, Zacks Investment Research cut Emergent Biosolutions from a hold rating to a sell rating in a report on Tuesday, February 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $39.40.

Shares of Emergent Biosolutions (EBS) traded up 2.09% during mid-day trading on Friday, hitting $34.65. The company had a trading volume of 847,092 shares. Emergent Biosolutions has a 12 month low of $24.47 and a 12 month high of $39.21. The firm has a 50-day moving average price of $31.21 and a 200 day moving average price of $30.72. The firm has a market capitalization of $1.42 billion, a P/E ratio of 27.54 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $0.08. The firm had revenue of $116.90 million for the quarter, compared to analyst estimates of $121.30 million. Emergent Biosolutions had a return on equity of 11.92% and a net margin of 10.36%. The business’s revenue for the quarter was up 13.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 earnings per share. On average, equities research analysts forecast that Emergent Biosolutions will post $1.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Emergent Biosolutions, Inc. (EBS) Upgraded to “Buy” by BidaskClub” was posted by sleekmoney and is the property of of sleekmoney. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://sleekmoney.com/emergent-biosolutions-inc-ebs-upgraded-to-buy-by-bidaskclub/1937638.html.

In other news, EVP Adam Havey sold 11,419 shares of Emergent Biosolutions stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $28.62, for a total value of $326,811.78. Following the completion of the sale, the executive vice president now owns 26,046 shares of the company’s stock, valued at $745,436.52. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 16.50% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue increased its stake in Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 100 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in Emergent Biosolutions by 1.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 10,720 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 180 shares during the period. Louisiana State Employees Retirement System increased its stake in Emergent Biosolutions by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 300 shares during the period. Arizona State Retirement System increased its stake in Emergent Biosolutions by 1.7% in the first quarter. Arizona State Retirement System now owns 18,060 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 300 shares during the period. Finally, Bank of Montreal Can increased its stake in Emergent Biosolutions by 0.4% in the first quarter. Bank of Montreal Can now owns 113,198 shares of the biopharmaceutical company’s stock worth $3,288,000 after buying an additional 473 shares during the period. 85.92% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/emergent-biosolutions-inc-ebs-upgraded-to-buy-by-bidaskclub/1937638.html

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *